Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling

被引:17
|
作者
Bogaards, JJP [1 ]
Freidig, AP [1 ]
van Bladeren, PJ [1 ]
机构
[1] TNO, Nutr & Food Res, Div Toxicol, NL-3700 AJ Zeist, Netherlands
关键词
isoprene; metabolism; cytochrome P450; glutathione S-transferase; epoxide hydrolase; PBPK modelling;
D O I
10.1016/S0009-2797(01)00276-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The present study was designed to explain the differences in isoprene toxicity between mouse and rat based on the liver concentrations of the assumed toxic metabolite isoprene diepoxide. In addition, extrapolation to the human situation was attempted. For this purpose, enzyme kinetic parameters K-m and V-max were determined in vitro in mouse, rat and human liver microsomes/cytosol for the cytochrome P450-mediated formation of isoprene mono- and diepoxides, epoxide hydrolase mediated hydrolysis of isoprene mono- and diepoxides, and the glutathione S-transferases mediated conjugation of isoprene monoepoxides. Subsequently, the kinetic parameters were incorporated into a physiologically-based pharmacokinetic model, and species differences regarding isoprene diepoxide levels were forecasted. Almost similar isoprene diepoxide liver and lung concentrations were predicted in mouse and rat, while predicted levels in humans were about 20-fold lower. However, when interindividual variation in enzyme activity was introduced in the human model, the levels of isoprene diepoxide changed considerably. It was forecasted that in individuals having both an extensive oxidation by cytochrome P450 and a low detoxification by epoxide hydrolase, isoprene diepoxide concentrations in the liver increased to similar concentrations as predicted for the mouse. However, the interpretation of the latter finding for human risk assessment is ambiguous since species differences between mouse and rat regarding isoprene toxicity could not be explained by the predicted isoprene diepoxide concentrations. We assume that other metabolites than isoprene diepoxide or different carcinogenic response might play a key role in determining the extent of isoprene toxicity. In order to confirm this, in vivo experiments are required in which isoprene epoxide concentrations will be established in rats and mice. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:247 / 265
页数:19
相关论文
共 50 条
  • [1] Prediction of adverse male reproductive health effects by integrating in vitro data and physiologically-based kinetic modelling
    Taxvig, C.
    Scholze, M.
    Kortenkamp, A.
    Boberg, J.
    Svingen, T.
    Ermler, S.
    Hermann, S. S.
    Lykkeberg, A. K.
    Pedersen, M.
    Hass, U.
    Bonomo, S.
    Vinggaard, A. M.
    TOXICOLOGY LETTERS, 2018, 295 : S61 - S61
  • [2] APPLICATION OF PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELLING TO ASSESS THE PREDICTION OF RENAL AND HEPATIC GLUCURONIDATION CLEARANCE FROM IN VITRO DATA
    Houston, James
    Gill, Katherine
    Gertz, Michael
    Galetin, Aleksandra
    DRUG METABOLISM REVIEWS, 2012, 44 : 42 - 43
  • [3] Prediction of interindividual variation in drug plasma levels in vivo from individual enzyme kinetic data and physiologically based pharmacokinetic modeling
    Bogaards, JJP
    Hissink, EM
    Briggs, M
    Weaver, R
    Jochemsen, R
    Jackson, P
    Bertrand, M
    van Bladeren, PJ
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 12 (02) : 117 - 124
  • [4] A Physiologically-Based Pharmacokinetic Model for the Prediction of Monoclonal Antibody Pharmacokinetics From In Vitro Data
    Jones, Hannah M.
    Zhang, Zhiwei
    Jasper, Paul
    Luo, Haobin
    Avery, Lindsay B.
    King, Lindsay E.
    Neubert, Hendrik
    Barton, Hugh A.
    Betts, Alison M.
    Webster, Robert
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2019, 8 (10): : 738 - 747
  • [5] Evaluation of Age-Related Pyrethroid Pharmacokinetic Differences in Rats: Physiologically-Based Pharmacokinetic Model Development Using In Vitro Data and In Vitro to In Vivo Extrapolation
    Song, Gina
    Moreau, Marjory
    Efremenko, Alina
    Lake, Brian G.
    Wu, Huali
    Bruckner, James V.
    White, Catherine A.
    Osimitz, Thomas G.
    Creek, Moire R.
    Hinderliter, Paul M.
    Clewell, Harvey J.
    Yoon, Miyoung
    TOXICOLOGICAL SCIENCES, 2019, 169 (02) : 365 - 379
  • [6] Assessment of cadmium as a tobacco smoke toxicant using in vitro genotoxicity and physiologically-based pharmacokinetic (PBPK) Modelling
    Cunningham, Fiona
    Fiebelkorn, Stacy
    Dillon, Debbie
    Meredith, Clive
    TOXICOLOGY LETTERS, 2014, 229 : S159 - S159
  • [7] Foetal and neonatal exposure prediction and dosing evaluation for ampicillin using a physiologically-based pharmacokinetic modelling approach
    Li, Sanwang
    Xie, Feifan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (04) : 1402 - 1412
  • [8] GENOTYPE-BASED IN VITRO-IN VIVO EXTRAPOLATION (IVIVE) OF EFAVIRENZ PHARMACOKINETICS USING A PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODEL
    Xu, C.
    Quinney, S.
    Guo, Y.
    Desta, Z.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S30 - S30
  • [9] Application of in vitro data in physiologically-based kinetic models for quantitative in vitro-in vivo extrapolation: A case-study for baclofen
    Kasteel, Emma E. J.
    Lautz, Leonie S.
    Culot, Maxime
    Kramer, Nynke, I
    Zwartsen, Anne
    TOXICOLOGY IN VITRO, 2021, 76
  • [10] Physiologically Based Pharmacokinetic (PBPK) Modelling for In Vitro-In Vivo Extrapolation: Emphasis on the Use of Dissolution Data
    Ghate, Vivek M.
    Chaudhari, Pinal
    Lewis, Shaila A.
    DISSOLUTION TECHNOLOGIES, 2019, 26 (03): : 18 - 27